Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a dual acting kappa opioid receptor agonist and a mu opioid receptor antagonist ('KAMA'), hypothesized to reduce cough hypersensitivity by modulating both central neural pathways and peripheral airway nerves.

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Exchange

NASDAQ-GM

Region

North America

Website

trevitherapeutics.com